Research on markers for omalizumab therapy in asthma
Not Applicable
- Conditions
- asthma
- Registration Number
- JPRN-UMIN000018619
- Lead Sponsor
- ational Hospital Organization, Tokyo National Hospital Clinical Research Center
- Brief Summary
GETE assessment showed 19 responders (61.3%) and 12 non-responders (38.7%). Responders showed significantly higher levels of CXCL10 and IL-12 at baseline compared to non-responders . ROC curves to distinguish responders from non-responders using the baseline serum CXCL10 level showed a good AUC of 0.83. At 32 weeks of omalizumab therapy, serum CXCL10 tended to be increased and serum IL-12 tended to be decreased . On the other hand, serum IL-5 and PDGF were significantly decreased .
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 31
Inclusion Criteria
Not provided
Exclusion Criteria
Patients without researcher's assent.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method